Navigation Links
Worming our way to new treatments for Alzheimer's disease
Date:3/7/2013

Philadelphia, PA, March 7, 2013 According to a 2012 World Health Organization report, over 35 million people worldwide currently have dementia, a number that is expected to double by 2030 (66 million) and triple by 2050 (115 million). Alzheimer's disease, the most common form of dementia, has no cure and there are currently only a handful of approved treatments that slow, but do not prevent, the progression of symptoms.

New drug development, no matter the disease, is a slow, expensive, and risky process. Thus, innovative techniques to study and assess the possibilities of already-existing drugs for different diseases can be used to alleviate the traditional burdens of cost and time. Detailed in their new article in Biological Psychiatry, researchers from the University of Washington, led by Dr. Brian Kraemer, have developed an exciting new approach to screening potential new treatments for Alzheimer's disease using C. elegans, a small transparent worm.

Their focus was on tau, a protein involved in maintaining brain cell structure. In Alzheimer's disease and related disorders, tau protein becomes abnormally modified and forms clumps of protein called aggregates. These aggregates are a hallmark of the dying nerve cells in Alzheimer's disease and other related disorders. Diseases with abnormal tau are called tauopathies.

Dr. Kraemer's lab previously developed a worm model for tauopathy by expressing human tau in C. elegans nerve cells. This model has behavioral abnormalities, accumulates abnormal tau protein, and exhibits loss of nerve cellsall of which are general features of Alzheimer's disease.

Using their worm model for this study, they screened a library of 1,120 drugs approved for human use and tested each at three different concentrations to identify compounds that suppress the effects of abnormal tau aggregation.

"We have identified six compounds capable of reliably alleviating tau induced behavioral abnormalities in our C. elegans model for tauopathy. In a human cultured cell model for abnormal tau protein, we have also seen that azaperone treatment can decrease the amount of abnormal tau," said Kraemer.

Azaperone, an antipsychotic drug, normally binds to certain dopamine receptors found in nerve cells. They demonstrated that removing those receptors in either C. elegans or human cells has the same effect as azaperone treatment, indicating that azaperone and related drugs should alter abnormal tau accumulation. Other antipsychotic drugs also have a similar effect to azaperone.

Tests of these compounds for anti-tau properties are now underway in existing mouse models of Alzheimer's disease.

"This study is an exemplary instance of how a simple C. elegans model system may be used to rapidly screen drugs for diseases and evaluate mechanism of action," said Drs. Sangeetha Iyer and Jonathan Pierce-Shimomura, authors of a commentary that accompanies this article.

Dr. John Krystal, Editor of Biological Psychiatry, agrees and added: "Studying the worm, C. elegans, has already provided us with fundamental insights into how the brain develops. The new approach described by McCormick and colleagues suggests that this animal model may be a powerful new approach to studying novel treatments that prevent its decline."


'/>"/>

Contact: Rhiannon Bugno
Biol.Psych@utsouthwestern.edu
214-648-0880
Elsevier
Source:Eurekalert

Related medicine news :

1. Global health researchers urge integrating de-worming into HIV care in Africa
2. Recon 2 modeling may help tailor treatments for patients with metabolic diseases, cancer
3. DNDi receives BBVA Foundation award for delivering new treatments for neglected diseases
4. Best Glaucoma Treatments Still a Puzzle, Task Force Reports
5. San Bruno, CA Dentist Dr. Bradley Parker Receives Top Reviews for New Laser Assisted Dental Treatments
6. ADHD Treatments Not Working for Most Young Children
7. Research fellowships to advance medical treatments and bring new science to market
8. 3 NIH-sponsored clinical trials test influenza treatments
9. World Stem Cells, LLC. facilitates Stem Cell Treatments In Cancun at World Stem Cells Clinic
10. Beware Fake Flu Treatments, FDA Warns
11. hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces New Alternative to Stomach Botox Injections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 24, 2017 , ... The health ... Annual Enrollment Period (AEP) and the Open Enrollment Period (OEP). 2016 was no ... Mainly, people are witnessing higher deductibles, rising premiums, and few choices with their ...
(Date:1/24/2017)... ... January 24, 2017 , ... PeroxyChem Food ... Assurance Control Equipment (PACE), at the International Production and Processing Expo (IPPE) in ... highlight the new technology that is used in poultry processing facilities to provide ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... was recently accepted as a Registered Trademark by the United States Patent and ... a similar name which could confuse consumers into thinking that other products are ...
(Date:1/24/2017)... ... January 24, 2017 , ... Learn to use popular ... or even in relationships. Course offered by Dr. Carol Francis at PVNET on ... limited seating and the many hands-on experiences. , Dr. Carol Francis shows ...
(Date:1/24/2017)... ... January 24, 2017 , ... Seceon , the ... in real-time, today announced a strategic partnership with Paramount , the Middle ... and protect their critical information assets and infrastructure, in a comprehensive and cost ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... , January 24, 2017 For today, ... GENE ), Alder Biopharmaceuticals Inc. (NASDAQ: ... ), and Egalet Corp. (NASDAQ: EGLT ). These ... lower on Monday, January 23 rd , 2017, with the ... health care companies in the S&P 500 also were down ...
(Date:1/24/2017)... YORK , Jan. 23, 2017 Laboratory ... the global use of mass spectrometry in both clinical ... current ,MS analysis, global market size of $6.8 billion ... the next four years, profiles the use of mass ... encompassing 21 countries. This study investigated growth in the ...
(Date:1/24/2017)... , January 23, 2017 ArisGlobal, ... life sciences, announces agClinical 3.3, the latest version of ... enables life science organizations to confidently and efficiently meet ... better manage the electronic trial master file so that ... ...
Breaking Medicine Technology: